Gilead Adefovir Approval Awaits "Unequivocal" Evidence Of Efficacy At 60 mg
Executive Summary
Gilead has begun enrollment in two placebo-controlled trials of a 60 mg dose of adefovir dipivoxil that could provide sufficient evidence to prompt a reconsideration of the HIV therapy by FDA's Antiviral Drugs Advisory Committee.
You may also be interested in...
Gilead Hepsera Launch: Lamivudine-Resistant Hep B Is First Target
Gilead's roll-out of Hepsera should be helped by a readily identifiable population of approximately 12,000 hepatitis B patients who are resistant to lamivudine (GlaxoSmithKline's Epivir-HBV)
Gilead Hepsera Launch: Lamivudine-Resistant Hep B Is First Target
Gilead's roll-out of Hepsera should be helped by a readily identifiable population of approximately 12,000 hepatitis B patients who are resistant to lamivudine (GlaxoSmithKline's Epivir-HBV)
Gilead Hepsera Clears FDA; Hepatitis B Therapy Will Cost $440 Per Month
Gilead is launching the hepatitis B agent Hepsera (adefovir) at a wholesale acquisition cost of $440 per month